Login to Your Account

Possible launch of brigatinib by early 2017

Ariad Pharmaceuticals Inc. agreed to pay mid-single-digit royalties on futures sales of Iclusig to PDL Biopharma Inc. in exchange for up to $200 million in financing intended to accelerate testing of brigatinib, an ALK inhibitor it is developing to treat NSCLC, and to continue its ongoing initiatives supporting both drugs. more »

Our Habitat for All Things Science
Metabolic switch may further tissue regeneration

Scientists made progress toward the goal of mammalian tissue regeneration with the publication of studies showing that mice could be induced to self-repair ear wounds by a drug treatment that increased levels of the transcription factor HIF-1alpha.

"We could convert an animal into a healer," senior author Ellen Heber-Katz, of the Lankenau Institute for Medical Research, told BioWorld Today.